Thanks tpizzazz24, your contributions are always on point...just another note, for an OTC stock I'm sure most every one would have to admit that Tapimmune has become in the past year a very credible company.
I have always and still think their path forward will be a partnership with a BP or an outright buyout candidate, I believe that there is much going on behind the scenes [positive] that we are not aware.
Put yourselves in the shoes of any BP that is in the immunology space especially cancer, interest must already be peaked and if I was in their shoes would only be waiting for clarification on Orphan and fast track and initiation of both trials.
I would like to see Glynn/John give an update on disease recurrence and stage compared to Herceptin or any others.
If disease recurrence surpasses any/all products on the market this will be highly coveted, the pressure to get their vaccine [early] to market will be overwhelming.
Think of it by mid 2016 Two Phase 11 trials running, the US economy is drowning in healthcare debt. To have a vaccine that performs "as well" or better than existing products should be fast tracked possibly approved much earlier than protocol dictates.
Once again the low cost and lack of toxicity will be a defining factor for any BP, even at this point their vaccine's [data] may be complimentary to most of them in this space filling in gaps or simply strengthening any BP products and lowering their cost to produce products.
Buyout or partial share swap would make sense to many, remember that Tapimmunes TAP technology back in 93 {Wilfred Jefferies inventor] had great success and even back then was touted as, a game changer.
Now in 2015 TAP, POLYSTART, FRa, Antigen presentation etc and we have yet to see how the vaccine performs with all three technology combined.
And we have all but forgotten about the infectious disease arm, and how the vaccine may be manipulated to work in many other areas other than Cancer.
A billion dollar valuation seems quite cheap when Herceptin alone brings in 6/7 billion a year and seems to be inferior to TPIV's vaccines.
Great to have a patent lawyer on board to strengthen/protect technology, and Polystart when up and running seems to hold great promise.
The 13.3 grant should have cleared up much doubt about vaccine working well moving forward.
Commercial product by mid 2016!!!
Thanks to RK for she dedicates more than anyone here, and the collaborative efforts of everyone are appreciated.
Thanks
BLU
